News About: Pharm. Industry
Listed pharmas increase advertising expenses by 14%
Listed pharmaceutical companies’ advertising expenses were increased by 14% over the last year. Moreover, there were 4 pharmaceutical companies which spent more than KRW 30 billion in advertisement between January and...
Kuhnil about to acquire approval of world’s first children sleep medication
On the 23rd of November, Kuhnil Pharm(CEO Young-Joong Kim, Jae-Hee Choi) announced it was informed the Phase 3 clinical trial of Circadilly that will be introduced from Israeli Neurim was successfully completed.
Circ...
I-SENS acquires U.S. diagnostic device company ‘CoaguSense’
On the 22nd, a biosensor company, I-SENS(CEO Geun-Sig Cha), signed an agreement to acquire 62% of the share of a U.S. blood coagulation monitoring company ‘CoaguSense’ and its control for USD 10.4 million.
According ...
CMG Pharm records highest growth rate of exports among listed pharmas
This year’s overseas sales/export growth rate of KOSDAQ listed pharmaceutical companies was 4 times higher than the one of KOSPI listed pharmaceutical companies.
According to the Yakup Shinmoon’s(www.yakup.com) analy...
Pharmas worrying whether to unveil successful outcomes in this political situation
“Should we, or shouldn’t we…”
Pharmaceutical companies have a concern lately. It is whether they should announce successful outcomes, which were created by R&D with great ef forts and challenges to the global market,...
Obligation to wear name tag for doctors and nurses from March next year
A bill to obligate medical personnel to wear a name tag will be considered.
The Ministry of Health and Welfare(MOHW) gave a pre-announcement of an amendment to the Medical Law, which chiefs of medical institute obli...
Listed pharmaceutical companies suffering from depressed work efficiency
As getting weakened in marketability, listed pharmaceutical companies are criticized to have lowered work efficiency as well.
According to the Yakup Shinmoon’s analysis result of KOSDAQ and KOSPI listed pharmaceutica...
Handok strengthens partnership with Alexion through renewal and new agreements
On the 17th, Handok(Chairman Young-Jin Kim) and U.S. Alexion Pharmaceuticals(CEO David L. Hallal) renewed the agreement of Soliris and signed a Korean sales agreement of rare disease therapies, ‘Strensiq’ and ‘Kanuma,...
Impact of Novartis’ rebate trial result in pharma industry
While the amendments to the Pharmaceutical Affairs Law and Medical Device Law to tighten punishment for pharmaceutical and medical device companies providing illegal rebates passed the National Assembly plenary sessio...
Celltrion acquires sales approval of antibody biosimilar ‘Truxima’ in KoreaCelltrion announced it acquired sales approval of its self-developed antibody biosimilar, CT-P10(brand name: Truxima, generic name: rituximab), from the Korea Ministry of Food a...
|
